Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (211-220 of 379) with videos related to

Pageof 38
Sort By:
Journal of the National Cancer Institute|May 2, 2007
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisHolger Schulz, Julia F Bohlius, Sven Trelle, et al.
International Journal of Radiation Oncology, Biology, Physics|August 14, 2021
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 TrialChristian Baues, Helen Goergen, Michael Fuchs, et al.
Leukemia & Lymphoma|May 30, 2013
Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trialBastian von Tresckow, Boris Boell, Dennis Eichenauer, et al.
The Oncologist|January 10, 2013
Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphomaNils Schoof, Jeremy Franklin, Robert Fürst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphomaRoland Schnell, Oliver Staak, Peter Borchmann, et al.
Blood|October 18, 2002
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphomaPeter Borchmann, Roland Schnell, Irene Fuss, et al.
International Journal of Cancer|July 9, 2004
Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivoBaerbel Matthey, Peter Borchmann, Roland Schnell, et al.
British Journal of Haematology|January 24, 2021
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Horst Müller, Leonard Elger, et al.
Blood|January 2, 2003
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupUte Rehwald, Holger Schulz, Marcel Reiser, et al.
Frontiers in Immunology|July 4, 2018
Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF PhenotypeBastian Dörsam, Teresa Bösl, Katrin S Reiners, et al.
Pageof 38

Showing results (211-220 of 379) with videos related to

Sort By:
Pageof 38
Journal of the National Cancer Institute|May 2, 2007
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisHolger Schulz, Julia F Bohlius, Sven Trelle, et al.
International Journal of Radiation Oncology, Biology, Physics|August 14, 2021
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 TrialChristian Baues, Helen Goergen, Michael Fuchs, et al.
Leukemia & Lymphoma|May 30, 2013
Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trialBastian von Tresckow, Boris Boell, Dennis Eichenauer, et al.
The Oncologist|January 10, 2013
Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphomaNils Schoof, Jeremy Franklin, Robert Fürst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2002
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphomaRoland Schnell, Oliver Staak, Peter Borchmann, et al.
Blood|October 18, 2002
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphomaPeter Borchmann, Roland Schnell, Irene Fuss, et al.
International Journal of Cancer|July 9, 2004
Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivoBaerbel Matthey, Peter Borchmann, Roland Schnell, et al.
British Journal of Haematology|January 24, 2021
Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Horst Müller, Leonard Elger, et al.
Blood|January 2, 2003
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupUte Rehwald, Holger Schulz, Marcel Reiser, et al.
Frontiers in Immunology|July 4, 2018
Hodgkin Lymphoma-Derived Extracellular Vesicles Change the Secretome of Fibroblasts Toward a CAF PhenotypeBastian Dörsam, Teresa Bösl, Katrin S Reiners, et al.
Pageof 38